Last update 06 Mar 2025
Guangzhou Angke Immune Biotechnology Co., Ltd

Guangzhou Angke Immune Biotechnology Co., Ltd

Joint Venture Company | Private Company | Subsidiary Company|
2018|
Guangdong Sheng, China
|
www.acroimmune.com

Overview

Basic Info

Introduction
AcroImmune BioTech. Co., Ltd. is a biotechnology company that specializes in the research, development, and commercialization of innovative biologics and immunotherapies. AcroImmune's team of experts in immunology, molecular biology, and translational medicine is committed to delivering transformative solutions that change the lives of patients worldwide. Founded in 2005 and headquartered in Taiwan.

Tags

Neoplasms
Digestive System Disorders
Other Diseases
Monoclonal antibody
Antibody
Biological products

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Disease DomainCount
Neoplasms12
Hemic and Lymphatic Diseases2
Immune System Diseases1
Infectious Diseases1
Endocrinology and Metabolic Disease1
Top 5 Drug TypeCount
Monoclonal antibody6
Antibody3
Biological products1
Antibody drug conjugate (ADC)1
Bispecific T-cell Engager (BiTE)1
Top 5 TargetCount
CD24(CD24 molecule)4
CD38(Lymphocyte differentiation antigen CD38)1
TIGIT(T cell immunoglobulin and ITIM domains)1
PD-1 x SIRPα1
VISTA(V-domain Ig suppressor of T-cell activation)1

Related

14
Drugs associated with Guangzhou Angke Immune Biotechnology Co., Ltd
Gotistobart
Target
CTLA4
Mechanism
CTLA4 inhibitors
Active Org.
OncoC4, Inc.OncoC4, Inc.Startup [+2]
Originator Org.
OncoImmune, Inc.OncoImmune, Inc.
Active Indication
metastatic non-small cell lung cancer [+25]
Inactive Indication-
Drug Highest PhasePhase 3
First Approval Ctry. / Loc.-
First Approval Date-
AI-071
Target
CD24 x Siglec
Mechanism
CD24 inhibitors [+1]
Active Org.
Guangzhou Angke Immune Biotechnology Co., LtdGuangzhou Angke Immune Biotechnology Co., Ltd [+1]
Originator Org.
Guangzhou Angke Immune Biotechnology Co., LtdGuangzhou Angke Immune Biotechnology Co., Ltd
Active Indication
COVID-19 [+2]
Inactive Indication-
Drug Highest PhasePhase 1
First Approval Ctry. / Loc.-
First Approval Date-
ONC-782
Target
CD24
Mechanism
CD24 inhibitors
Active Org.
OncoC4, Inc.OncoC4, Inc.Startup [+1]
Originator Org.
OncoC4, Inc.OncoC4, Inc.Startup
Active Indication
Hematologic Neoplasms [+2]
Inactive Indication-
Drug Highest PhasePreclinical
First Approval Ctry. / Loc.-
First Approval Date-
3
Clinical Trials associated with Guangzhou Angke Immune Biotechnology Co., Ltd
CTR20232927
/ SuspendedPhase 3
比较ONC-392与多西他赛治疗经PD-1/PD-L1抑制剂治疗后进展的转移性非小细胞肺癌受试者的两阶段、随机对照多中心III期临床研究
[Translation] A two-stage, randomized, controlled, multicenter phase III clinical study comparing ONC-392 with docetaxel in patients with metastatic non-small cell lung cancer who have progressed after PD-1/PD-L1 inhibitor therapy
CTR20223247
/ Active, not recruitingPhase 1
评估ONC-392注射液在局部晚期或转移性肝细胞癌、食管癌、胃癌和肛管癌受试者中的安全性与有效性的单臂、开放、多中心Ib期临床研究
[Translation] A single-arm, open-label, multicenter Phase Ib clinical study to evaluate the safety and efficacy of ONC-392 injection in subjects with locally advanced or metastatic hepatocellular carcinoma, esophageal cancer, gastric cancer, and anal canal cancer
CTR20202042
/ CompletedPhase 1
ONC-392注射液治疗晚期实体瘤和非小细胞肺癌的安全性、药代动力学（Pharmacokinetics，PK）和有效性的开放标签Ia/Ib期临床研究
[Translation] An open-label Phase Ia/Ib clinical study of the safety, pharmacokinetics (PK) and efficacy of ONC-392 injection in the treatment of advanced solid tumors and non-small cell lung cancer
100 Clinical Results associated with Guangzhou Angke Immune Biotechnology Co., Ltd
Login to view more data
0 Patents (Medical) associated with Guangzhou Angke Immune Biotechnology Co., Ltd
Login to view more data
100 Deals associated with Guangzhou Angke Immune Biotechnology Co., Ltd
Login to view more data
100 Translational Medicine associated with Guangzhou Angke Immune Biotechnology Co., Ltd
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 17 Mar 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Discovery
3
9
Preclinical
Phase 1
2
3
Other
Login to view more data

Current Projects

Drug(Targets)IndicationsGlobal Highest Phase
AI-071
 ( CD24 x Siglec )		Inflammation
More
Phase 1
AI-064
 ( CTLA4 x VEGF )		Neoplasms
More
Preclinical
ONC-783
 ( CD24 x CD3 )		Neoplasms
More
Preclinical
ONC-781
 ( CD24 )		Neoplasms
More
Preclinical
AI-061
 ( CTLA4 x PD-1 )		Neoplasms
More
Preclinical
Login to view more data

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free